Advanced-stage Hodgkin lymphoma: US/chest radiography for detection of relapse in patients in first complete remission - A randomized trial of routine surveillance imaging procedures

Radiology

Volumn 272, Issue 1, 2014, Pages 262-274

  Picardi, Marco ^a   Pugliese, Novella ^a   Cirillo, Michele ^a   Zeppa, Pio ^b   Cozzolino, Imma ^a   Ciancia, Giuseppe ^a   Pettinato, Guido ^a   Salvatore, Claudia ^c   Quintarelli, Concetta ^a   Pane, Fabrizio ^a  

^a UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^b Advanced Biomedical Science Federico II University Medical School ^*  (Italy)

^c UNIVERSITY OF MOLISE   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

ADOLESCENT; ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER REGRESSION; COHORT ANALYSIS; COMPUTED TOMOGRAPHY SCANNER; COMPUTER ASSISTED EMISSION TOMOGRAPHY; CONTRAST ENHANCEMENT; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC TEST ACCURACY STUDY; ECHOGRAPHY; FEMALE; FOLLOW UP; HISTOLOGY; HODGKIN DISEASE; HUMAN; HUMAN TISSUE; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PATIENT COMPLIANCE; PATIENT MONITORING; PREDICTIVE VALUE; PRIORITY JOURNAL; RADIATION HAZARD; RADIOGRAPHY DEVICE; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; STANDARD; THORAX RADIOGRAPHY; TREATMENT WITHDRAWAL;

ADOLESCENT; ADULT; AGED; ALGORITHMS; COMBINED MODALITY THERAPY; FEMALE; FLUORODEOXYGLUCOSE F18; HODGKIN DISEASE; HUMANS; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; POSITRON-EMISSION TOMOGRAPHY; RADIATION DOSAGE; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, X-RAY COMPUTED; ULTRASONOGRAPHY, DOPPLER;

EID: 84903747179     PISSN: 00338419     EISSN: 15271315     Source Type: Journal    
DOI: 10.1148/radiol.14132154     Document Type: Article

References (39)

1. Diehl V, Stein H, Hummel M, et al. Hodgkin's lymphoma: biology and treatment strategies for primary, refractory, and relapsed disease. Hematol Am Soc Hematol Educ Prog 2003:225-247.
2. Duggan DB, Petroni GR, Johnson JL, et al. Randomized comparison of ABVD and MOPP/ABV hybrid for the treatment of advanced Hodgkin's disease: report of an intergroup trial. J Clin Oncol 2003;21(4):607-614. (Pubitemid 46621893)
3. Torrey MJ, Poen JC, Hoppe RT. Detection of relapse in early-stage Hodgkin's disease: role of routine follow-up studies. J Clin Oncol 1997;15(3):1123-1130. (Pubitemid 27106298)
4. Goldschmidt N, Or O, Klein M, Savitsky B, Paltiel O. The role of routine imaging procedures in the detection of relapse of patients with Hodgkin lymphoma and aggressive non-Hodgkin lymphoma. Ann Hematol 2011;90(2):165-171.
5. Hoppe RT, Advani RH, Ai WZ, et al. Hodgkin lymphoma, version 2.2012 featured updates to the NCCN guidelines. J Natl Compr Canc Netw 2012;10(5):589-597.
6. Ng A, Constine LS, Advani R, et al. ACR Appropriateness Criteria: follow-up of Hodgkin's lymphoma. Curr Probl Cancer 2010;34(3):211-227.
7. Armitage JO. Who benefits from surveillance imaging? J Clin Oncol 2012;30(21):2579-2580.
8. Cheson BD. Role of functional imaging in the management of lymphoma. J Clin Oncol 2011;29(14):1844-1854.
9. El-Galaly TC, Mylam KJ, Brown P, et al. Positron emission tomography/computed tomography surveillance in patients with Hodgkin lymphoma in first remission has a low positive predictive value and high costs. Haematologica 2012;97(6):931-936.
10. Petrausch U, Samaras P, Veit-Haibach P, et al. Hodgkin's lymphoma in remission after first-line therapy: which patients need FDG-PET/CT for follow-up? Ann Oncol 2010;21(5):1053-1057.
11. Mocikova H, Obrtlikova P, Vackova B, Trneny M. Positron emission tomography at the end of first-line therapy and during follow-up in patients with Hodgkin lymphoma: a retrospective study. Ann Oncol 2010;21(6):1222-1227.
12. Zinzani PL, Stefoni V, Tani M, et al. Role of [18F]fluorodeoxyglucose positron emission tomography scan in the follow-up of lymphoma. J Clin Oncol 2009;27(11):1781-1787.
13. Brusamolino E, Bacigalupo A, Barosi G, et al. Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up. Haematologica 2009;94(4):550-565.
14. Zinzani PL, Tani M, Trisolini R, et al. Histological verification of positive positron emispatient sion tomography findings in the follow-up of patients with mediastinal lymphoma. Haematologica 2007;92(6):771-777. (Pubitemid 350155302)
15. .Willowson KP, Bailey EA, Bailey DL. A retrospective evaluation of radiation dose associated with low dose FDG protocols in whole-body PET/CT. Australas Phys Eng Sci Med 2012;35(1):49-53.
16. Huang B, Law MW, Khong P-L. Whole-body PET/CT scanning: estimation of radiation dose and cancer risk. Radiology 2009;251(1):166-174.
17. Picardi M, Gennarelli N, Ciancia R, et al. Randomized comparison of power Doppler ultrasound-directed excisional biopsy with standard excisional biopsy for the characterization of lymphadenopathies in patients with suspected lymphoma. J Clin Oncol 2004;22(18):3733-3740. (Pubitemid 41095214)
18. Picardi M, Ciancia R, De Renzo A, et al. Estimation of bulky lymph nodes by power Doppler ultrasound scanning in patients with Hodgkin's lymphoma: a prospective study. Haematologica 2006;91(7):960-963. (Pubitemid 44023152)
19. Picardi M, Soricelli A, Pane F, et al. Contrast-enhanced harmonic compound US of the spleen to increase staging accuracy in patients with Hodgkin lymphoma: a prospective study. Radiology 2009;251(2):574-582.
20. Choudhry S, Gorman B, Charboneau JW, et al. Comparison of tissue harmonic imaging with conventional US in abdominal disease. RadioGraphics 2000;20(4):1127-1135.
21. Blank W, Schuler A, Wild K, Braun B. Transthoracic sonography of the mediastinum. Eur J Ultrasound 1996;3(2):179-190. (Pubitemid 26180785)
22. De Pascale A, Giorcelli R, Garofalo G, et al. Follow-up of mediastinal lymphoma: role of ultrasonography. Radiol Med (Torino) 2006;111(6):759-772. (Pubitemid 44496524)
23. Toma P, Granata C, Rossi A, Garaventa A. Multimodality imaging of Hodgkin disease and non-Hodgkin lymphomas in children. RadioGraphics 2007;27(5):1335-1354.
24. Müller NL, Webb WR, Gamsu G. Paratracheal lymphadenopathy: radiographic findings and correlation with CT. Radiology 1985;156(3):761-765. (Pubitemid 16254606)
25. Gibbs JM, Chandrasekhar CA, Ferguson EC, Oldham SA. Lines and stripes: where did they go? - From conventional radiography to CT. RadioGraphics 2007;27(1):33-48.
26. Harris NL, Jaffe ES, Diebold J, et al. The World Health Organization classification of neoplasms of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting - Airlie House, Virginia, November, 1997. Hematol J 2000;1(1):53-66.
27. Lister TA, Crowther D, Sutcliffe SB, et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. J Clin Oncol 1989;7(11):1630-1636. (Pubitemid 19272832)
28. Picardi M, Soricelli A, Grimaldi F, Nicolai E, Gallamini A, Pane F. Fused FDG-PET/contrast-enhanced CT detects occult subdiaphragmatic involvement of Hodgkin's lymphoma thereby identifying patients requiring six cycles of anthracycline-containing chemotherapy and consolidation radiation of spleen. Ann Oncol 2011;22(3):671-680.
29. Picardi M, De Renzo A, Pane F, et al. Randomized comparison of consolidation radiation versus observation in bulky Hodgkin's lymphoma with post-chemotherapy negative positron emission tomography scans. Leuk Lymphoma 2007;48(9):1721-1727. (Pubitemid 47386707)
30. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17(4):1244-1253. (Pubitemid 29162950)
31. Begg CB, Iglewicz B. A treatment allocation procedure for sequential clinical trials. Biometrics 1980;36(1):81-90.
32. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31(1):103-115.
33. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG; CONSORT Group. Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 2012;308(24):2594-2604.
34. Bossuyt PM, Reitsma JB, Bruns DE, et al. Towards complete and accurate reporting of studies of diagnostic accuracy: The STARD Initiative. Radiology 2003;226(1):24-28. (Pubitemid 36163903)
35. Tunes da Silva G, Logan BR, Klein JP. Methods for equivalence and noninferiority testing. Biol Blood Marrow Transplant 2009;15(1 Suppl):120-127.
36. Cheson BD, Pfistner B, Juweid ME, et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007;25(5):579-586. (Pubitemid 350002966)
37. Engert A, Eichenauer DA, Dreyling M; ESMO Guidelines Working Group. Hodgkin's lymphoma: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann Oncol 2009;20(Suppl 4):108-109.
38. Levine JM, Weiner M, Kelly KM. Routine use of PET scans after completion of therapy in pediatric Hodgkin disease results in a high false positive rate. J Pediatr Hematol Oncol 2006;28(11):711-714. (Pubitemid 44786433)
39. Velasco Garrido M, Gerhardus A, Røttingen J-A, Busse R. Developing Health Technology Assessment to address health care system needs. Health Policy 2010;94(3): 196-202.